Abstract| Volume 23, ISSUE 10, SUPPLEMENT , S15, October 2017

Intra Venous Infusion of Nano-ONO1301 Improve Pulmonary Hypertension in Rat Model

      Introduction: We hypothesized that intra venous infusion of newly developed nano-prostacyclin agonist, ONO1301nano, may have some potentials in targeted delivery to damaged lung and improving pulmonary hypertension in rat model. Methods & Results: PAH model rats were induced by the subcutaneous injection with SU5416 (20 g/kg), exposing to chronic hypoxia for 21 days, and normoxia after hypoxia. Treatment group was injected ONO1301nano (3 g/kg) every 7 days cycle after exposure to normoxia for 14 days in normoxia environment. In vivo, the fluorescent images showed that significantly larger number of texas red-labeled nano sized particles were detected in the damaged lung by intravenous administration compared with normal rats (P < .05). Immunostains revelaed that nano particles labeled by texas-red were detected in vimentin positive cells in the lung tissue. On catheterization, the right ventricle pressure/left ventricle pressure was significantly improved in ONO1301nano treatment group compared with the control (P < .01). Histological assessment revealed that the percent medial wall thickness in pulmonary vasculature were significantly ameliorated in treated group (P < .01). In vitro, the expression levels of VEGF and HGF in cultured fibroblasts were increased. Conclusions: Intra venous infusion of ONO1301nano improved pulmonary hemodynamically and histologically in PH model rats with selective delivery to damaged lung, suggesting Nano-prostacyclin agonist delivery system may have potential in new drug for PAH.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect